Is limb lengthening surgery safe in 2026?

Paley's classification sorts events into problems (resolve without surgery), obstacles (need a procedure but leave no lasting effect), and true complications (a permanent sequela or a failed goal). Series report these separately, and the headline percentage usually refers only to the last category — which is why a 'one in three' figure is not the same as 'two in three sail through'.

The 2025 meta-analysis of 489 cosmetic patients is the clearest picture of the lesser events. External fixation produced problems in 56% of patients and obstacles in 48%; intramedullary nails produced problems in 37% and obstacles in 42%. Pin-site irritation, transient calf tingling, joint stiffness and a few degrees of lost knee flexion live in those two bands. Expect them.

True complications are where outcomes change: non-union, permanent nerve injury, deep infection, vascular injury, refracture. That band sits at roughly 5-15% across cosmetic series — 10% for external fixation in the 2025 meta-analysis, 0.15 events per patient in the 795-patient systematic review. Internal-nail data sits lower: in the 983-segment PRECICE and FITBONE review (Acta Orthopaedica, PMC7919879), 34% of segments had a complication of any grade, but only 5% failed to reach the treatment goal and 3% ended with new pathology or permanent sequelae.

Reading a clinic's complication rate without knowing how events were graded is meaningless. A clinic that reports 8% may be counting only true complications. A clinic that reports 35% may be counting every pin-site dressing change. The denominator matters more than the percentage.

Method choice changes the complication profile but not as dramatically as patients assume. Internal nails are the safest category in cosmetic indication. Hybrid LON sits in the middle. Pure external-fixator Ilizarov sits at the high end and is now mostly reserved for reconstructive cases.

The ranges below are pulled from our method spec library, cross-checked against published case series and the FITBONE/PRECICE Acta Orthopaedica systematic review. They describe cosmetic indication only, reconstructive cases (limb-length discrepancy, dwarfism, post-trauma) trend higher across every method because the patients are older or sicker.

Four events dominate the serious-complication band. Each one can change the timeline by 3-12 months, cost an extra $5,000-$25,000 to treat, and in a small share of cases never fully resolves.

Non-union is the most common. The new bone fails to harden on schedule, and the surgeon either dynamises the implant, adds bone graft, or both. Internal-nail series cluster at 2-4%; LON and Ilizarov series cluster at 6-8%. Smoking, distraction faster than 1 mm/day, low vitamin D, and patient age above 45 are the documented risk factors.

Nerve injury is the second most common. The peripheral nerves stretch alongside the bone, most tolerate it, some do not. Tibial lengthening carries the higher risk because the peroneal nerve sits in a tight osseofascial tunnel below the knee. Published cosmetic series put nerve-related events in the low single-digit percent range. Most are transient and resolve over 3-9 months. A minority leave persistent foot drop, sensory loss, or chronic neuropathic pain. Slower distraction (0.75 mm/day) and prophylactic peroneal decompression are the documented risk-reduction levers, surgeon experience matters more here than method.

Deep infection is the third. Superficial pin-site infections affect 20-40% of external-fixator patients during distraction and clear with oral antibiotics. Deep infection, osteomyelitis or implant-tract sepsis, is a different category. Internal-nail series report 1-2%. LON and Ilizarov series report 3-4% because the pin-bone interface creates a permanent contamination route for the entire fixator period. Treatment is implant removal, 6-12 weeks of IV antibiotics, then reimplantation if the patient still wants to finish lengthening.

Refracture is the fourth and the most patient-driven. The new bone is fragile through consolidation, which runs 3-6 months past the end of distraction. Patients who return to running, basketball, or even aggressive walking at 6-9 months instead of 12+ months account for the disproportionate share of refractures in case-series follow-up. PRECICE patients have a false sense of recovery because there is no visible external hardware. The bone is still half-formed. Avoidable in roughly 90% of cases by following the surgeon's return-to-sport protocol.

The single most actionable variable in the safety literature is not in any method spec sheet. It is the surgeon's experience with the procedure. Higher-volume surgeons consistently report lower serious-complication rates than occasional operators, and that gap is wider than the difference between any two methods.

This is not a small variable. Choosing an experienced surgeon doing LON is generally safer than choosing an inexperienced one doing PRECICE, the cleaner method does not rescue a learning curve. The effect is also country-agnostic: a busy, experienced surgeon in Istanbul can be a safer choice than an occasional operator in the United States.

Several of the most experienced surgeons in this field appear in our directory. Dr. Dror Paley at the Paley Institute in West Palm Beach has performed limb lengthening since 1986 and draws patients from around the world. Prof. Yasser Elbatrawy runs a long-established limb-lengthening practice in Cairo. Dr. S. Robert Rozbruch directs the Limb Lengthening Service at Hospital for Special Surgery in New York, with a substantial mixed reconstructive and cosmetic caseload.

In Istanbul, a major hub for LON, Dr. Halil Buldu at LiveLifeTaller and Prof. Dr. Yüksel Yurttaş both run high-volume cosmetic practices, and Dr. Shahab Mahboubian runs an established PRECICE-focused practice in the United States. These are the kind of experienced, high-volume surgeons whose outcomes tend to sit at the low end of the serious-complication band.

Most published complication rates pool cosmetic and reconstructive indications. That overstates the cosmetic risk because reconstructive patients are older, sicker, or carrying complex deformity that adds intrinsic risk. Cosmetic-only series, patients who are otherwise healthy adults seeking stature gain, trend a few percentage points below the pooled headline.

Cosmetic-specific rates run roughly 25-35% any-complication and 3-8% serious. Reconstructive series trend 35-50% any-complication and 8-15% serious. The best-published cosmetic-only internal-nail series report single-digit serious-complication rates, and they tend to come from single high-volume surgeons, which underlines the volume effect.

Reading any claim of complication rate, ask which population it refers to. A clinic quoting 5% serious complications for cosmetic LL is in the credible range. A clinic quoting 1% serious complications without qualifying the indication, the grading scale, or the denominator is over-claiming. Cross-check against published series before you take a clinic's word for its own number.

The PRECICE Stryde nail received an FDA Class II recall in February 2021 after reports of corrosion at the telescoping junction and associated bone changes (osteolysis). NuVasive Specialized Orthopedics, now Globus Medical, since the September 2023 merger, paused US distribution and the recall remains active. Stryde is no longer implanted at any clinic in our directory as of 2026.

This is its own story and deserves its own page. We covered the timeline, the patient-monitoring protocol, and what to do if a clinic in 2026 still lists Stryde on its method menu in our dedicated explainer. Read that one for the detail, this article focuses on the larger safety picture beyond Stryde. The recall was a meaningful single-implant event but did not change the underlying safety profile of the PRECICE platform overall. PRECICE 2 and PRECICE Max remain in current use with the safety profile described above.

The questions below separate clinics that own their data from clinics that hope you do not ask. None require medical training to evaluate the answer.

First: how many cosmetic-indication lengthening cases did the lead surgeon perform in the last calendar year? A surgeon under 30 is low-volume by the literature. Over 75 is high-volume.

Second: what is your published any-complication rate, and what is your published serious-complication rate? A clinic that cannot separate the two has not measured them against a recognised grading scale such as Paley's classification.

Third: how many revision surgeries did the lead surgeon perform on their own cases last year? Hidden revision counts are the easiest way to suppress a complication number.

Fourth: what is the published rate of permanent, not transient, nerve injury? The transient-versus-permanent distinction is the line between proper follow-up and hope.

Fifth: will you share an anonymised list of complications from the last 24 months? A clinic that says yes is in a different category from a clinic that says no. Academic centres that publish their outcomes in the peer-reviewed literature are generally the most transparent on this point; many private clinics will decline. Treat the refusal as data.

Limb lengthening surgery in 2026 is safer than it was at any point in the last four decades. The internal-nail platform (PRECICE 2 and PRECICE Max) is mature, the surgical technique is standardised, and the high-volume centers publish outcomes that bear comparison with major joint replacement surgery, which carries a comparable any-complication rate in the 15-20% range.

The risk is real but quantifiable. A serious complication that changes the timeline, costs extra, or in a small share of cases never fully resolves affects 5-15% of patients depending on method and surgeon. A motivated, healthy adult who picks a high-volume surgeon and follows the recovery timeline lands at the low end of that band. A patient who chooses on price alone, who skips physiotherapy, or who returns to impact sport at month 6 lands somewhere closer to the high end.

The answer to the title question is not yes or no. It is conditional. Limb lengthening is safe enough to undergo if, and only if, three things are true. The surgeon is a high-volume, experienced cosmetic-lengthening specialist. The clinic owns its complication data and will discuss it on the record. The patient is willing to spend 9-18 months following a recovery protocol they do not get to negotiate. Patients who can answer yes to all three sit at the favourable end of the outcome distribution. Patients who cannot are exposed to a materially higher risk of complication and regret.